CancerVax Targets Hard to Treat Pancreatic Cancer
With limited options available to treat Pancreatic Ductal Adenocarcinoma (PDAC), the Company’s Universal Cancer Treatment Platform may provide hope for patients and doctors
CancerVax Successfully Uses Nobel Prize Chemistry to Achieve Universal Cancer Vaccine Targeting Milestone
The UCLA research team created a low cost and customizable lipid nanoparticle using “click chemistry” for precise targeting of cancer cell surface markers
CancerVax Announces Promising New Drug to Treat a Deadly Children’s Cancer
Company plans to launch FDA IND enabling studies needed to apply for approval to proceed with human trials
CancerVax Launches $5 Million Funding Round
Proceeds from the SEC qualified Reg A+ offering will allow the Company to continue work on its breakthrough cancer treatments
CancerVAX Reports Significant Progress on Universal Cancer Vaccine Development at UCLA
Three separate teams of physician scientists at UCLA working on three different parts of the project have made significant progress and are ready to merge their work into a complete proof-of-concept vaccine construct
CancerVAX Reports Positive Progress on Kids Cancer Immunotherapy Treatment
UCLA research team has successfully created 7 pre-clinical monoclonal antibody candidates for targeting Ewing sarcoma
